fingolimod hydrochloride has been researched along with carbon tetrachloride in 1 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (carbon tetrachloride) | Trials (carbon tetrachloride) | Recent Studies (post-2010) (carbon tetrachloride) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 8,804 | 11 | 2,582 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kong, Y; Tang, N; Wang, H; Wang, S | 1 |
1 other study(ies) available for fingolimod hydrochloride and carbon tetrachloride
| Article | Year |
|---|---|
FTY720, a sphingosine-1 phosphate receptor modulator, improves liver fibrosis in a mouse model by impairing the motility of bone marrow-derived mesenchymal stem cells.
Topics: Animals; Bone Marrow Cells; Carbon Tetrachloride; Cell Movement; Disease Models, Animal; Fibrosis; Fingolimod Hydrochloride; Immunosuppressive Agents; Liver Cirrhosis; Mesenchymal Stem Cells; Mice; Mice, Inbred ICR; Mice, SCID; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Wound Healing | 2014 |